Sansure Biotech Inc. (SHA:688289)
China · Delayed Price · Currency is CNY 18.34
+0.26 (1.44%)
At close: Mar 6, 2026
Sansure Biotech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,648 | 1,424 | 991.1 | 6,304 | 4,342 |
Other Revenue | - | 34.14 | 16.02 | 146.58 | 172.86 |
| 1,648 | 1,458 | 1,007 | 6,450 | 4,515 | |
Revenue Growth (YoY) | 13.04% | 44.78% | -84.39% | 42.88% | -5.22% |
Cost of Revenue | - | 279.71 | 280.96 | 2,912 | 1,283 |
Gross Profit | 1,648 | 1,178 | 726.15 | 3,538 | 3,232 |
Selling, General & Admin | - | 749.79 | 547.37 | 939.48 | 488.21 |
Research & Development | - | 276.64 | 194.81 | 331.2 | 186.84 |
Other Operating Expenses | 1,446 | 10.96 | 0.1 | 27.31 | 12.48 |
Operating Expenses | 1,446 | 1,051 | 747.23 | 1,344 | 706.01 |
Operating Income | 202.43 | 127.26 | -21.08 | 2,194 | 2,526 |
Interest Expense | - | -18.4 | -2.41 | -2.09 | -0.83 |
Interest & Investment Income | - | 97.53 | 308.41 | 48.35 | 32.53 |
Currency Exchange Gain (Loss) | - | 6.85 | 4.31 | 5.04 | -42.25 |
Other Non Operating Income (Expenses) | -27.08 | -1.77 | -9.15 | -7.94 | -1.61 |
EBT Excluding Unusual Items | 175.35 | 211.46 | 280.08 | 2,237 | 2,513 |
Impairment of Goodwill | - | - | - | -1.44 | - |
Gain (Loss) on Sale of Investments | - | -20.44 | 61.84 | 79.24 | 81.01 |
Gain (Loss) on Sale of Assets | - | -4.21 | -7.21 | -5.47 | 0.41 |
Asset Writedown | - | -1.25 | - | -15.1 | - |
Other Unusual Items | - | 75.04 | 75.76 | 21.3 | 21.37 |
Pretax Income | 175.35 | 260.61 | 410.48 | 2,316 | 2,616 |
Income Tax Expense | -22.8 | 34.34 | 62.31 | 379.21 | 373.68 |
Earnings From Continuing Operations | 198.15 | 226.27 | 348.17 | 1,937 | 2,243 |
Minority Interest in Earnings | - | 49.32 | 15.55 | 0.09 | 0.17 |
Net Income | 198.15 | 275.6 | 363.72 | 1,937 | 2,243 |
Net Income to Common | 198.15 | 275.6 | 363.72 | 1,937 | 2,243 |
Net Income Growth | -28.10% | -24.23% | -81.22% | -13.64% | -14.29% |
Shares Outstanding (Basic) | 583 | 586 | 587 | 585 | 589 |
Shares Outstanding (Diluted) | 583 | 586 | 587 | 585 | 589 |
Shares Change (YoY) | -0.61% | -0.05% | 0.26% | -0.59% | 6.55% |
EPS (Basic) | 0.34 | 0.47 | 0.62 | 3.31 | 3.81 |
EPS (Diluted) | 0.34 | 0.47 | 0.62 | 3.31 | 3.81 |
EPS Growth | -27.66% | -24.19% | -81.27% | -13.12% | -19.56% |
Free Cash Flow | - | -146.66 | -347.81 | 2,000 | 1,504 |
Free Cash Flow Per Share | - | -0.25 | -0.59 | 3.42 | 2.56 |
Dividend Per Share | - | 0.525 | 0.462 | 1.298 | 0.760 |
Dividend Growth | - | 13.59% | -64.39% | 70.77% | - |
Gross Margin | 100.00% | 80.82% | 72.10% | 54.85% | 71.58% |
Operating Margin | 12.28% | 8.73% | -2.09% | 34.01% | 55.94% |
Profit Margin | 12.02% | 18.90% | 36.12% | 30.03% | 49.68% |
Free Cash Flow Margin | - | -10.06% | -34.53% | 31.01% | 33.32% |
EBITDA | 343.06 | 267.89 | 79.8 | 2,269 | 2,571 |
EBITDA Margin | 20.81% | 18.37% | 7.92% | 35.18% | 56.96% |
D&A For EBITDA | 140.63 | 140.63 | 100.88 | 75.47 | 45.89 |
EBIT | 202.43 | 127.26 | -21.08 | 2,194 | 2,526 |
EBIT Margin | 12.28% | 8.73% | -2.09% | 34.01% | 55.94% |
Effective Tax Rate | - | 13.18% | 15.18% | 16.37% | 14.28% |
Revenue as Reported | - | 1,458 | 1,007 | 6,450 | 4,515 |
Advertising Expenses | - | 68.07 | 26.28 | 36.36 | 32.38 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.